Medifocus, Inc. to Present at the SeeThruEquity 3rd Annual Microcap Investor Conference & the Third Annual Marcum MicroCap Co...
May 27 2014 - 10:19AM
Marketwired
Medifocus, Inc. to Present at the SeeThruEquity 3rd Annual Microcap
Investor Conference and the Third Annual Marcum MicroCap Conference
COLUMBIA, MD and TORONTO, ON--(Marketwired - May 27, 2014) -
Medifocus, Inc. (OTCQX: MDFZF) (TSX-VENTURE: MFS) announced today
that, to increase investor's awareness and Medifocus, Inc.'s
visibility in the U.S. capital markets, it will present at both the
SeeThruEquity 3rd Annual Microcap Investor Conference and the Third
Annual Marcum MicroCap Conference in New York City.
On Wednesday, May 28, 2014 at the SeeThruEquity 3rd Annual
Microcap Investor Conference held at the Convene in Grand Central,
Medifocus, Inc.'s Chief Executive Officer, Dr. Augustine Cheung, is
scheduled to present at 1:00 pm ET in the Park Hub and will provide
an overview of Medifocus, Inc.'s business and growth strategy to
investors.
On Thursday, May 29, John Mon, Chief Operating Officer of
Medifocus, Inc., will be a featured presenter at the 3rd Annual
Marcum MicroCap Conference at the Grand Hyatt Hotel. The Company's
presentation is scheduled to begin at 2:30 p.m. ET.
Management will also be available to meet with members of the
investment community during one-on-one sessions being held at the
conferences.
About Medifocus, Inc.
Medifocus owns two fully developed technology platforms with
comprehensive United States and international patent protection:
(i) The Endo-thermotherapy Platform-a catheter-basis focused heat
technology platform that utilizes natural body openings to deliver
precise microwave thermotherapy to the diseased sites. The United
States Food and Drugs Administration (FDA) approved Prolieve
Thermodilatation System for the treatment of Benign Prostatic
Hyperplasia (BPH) was developed based on the Endo-thermotherapy and
is currently generating revenue; and (ii) the Adaptive Phased Array
(APA) Microwave Focusing Platform, invented by the Massachusetts
Institute of Technology, licensed to Medifocus directs precisely
focused microwave energy at tumor center to induce shrinkage or
eradication of tumors without undue harm to surrounding tissue.
Medifocus' APA 1000 Breast Cancer Treatment System, developed from
the APA technology platform, has received approval from the FDA and
Health Canada to conduct the pivotal Phase III clinical
trials. Medifocus believes that these two technology platforms
can provide the design basis for the development of multiple cancer
treatment systems for surface, subsurface and deep seated localized
and regional cancers. Please visit www.medifocusinc.com,
www.prolieve.com and
http://www.facebook.com/pages/Medifocus-Inc-Company-Page/546315028715627
for more details.
Forward-Looking Statements and Information
This news release contains "forward-looking statements" and
"forward-looking information", which may not be based on historical
facts. Forward-looking statements and forward-looking information,
include, but are not limited to, information and statements with
respect the structure and the proceeds of the Offering and the
expected use of the proceeds. Forward-looking statements are
frequently characterized by words such as "plan," "expect,"
"project," "intend," "believe," "anticipate", "estimate" and other
similar words, or statements that certain events or conditions
"may" or "will" occur. Forward-looking statements are based on the
opinions and estimates of management at the date the statements are
made. Such forward-looking statements and forward-looking
information involve known and unknown risks, uncertainties and
other factors that may cause the actual results events or
developments to be materially different from any future results,
events or developments expressed or implied by such forward-looking
statements or forward-looking information. These factors should be
considered carefully and readers are cautioned not to place undue
reliance on such forward-looking statements and forward-looking
information. Except as required by applicable securities laws,
Medifocus disclaims any obligation to update any such factors or to
publicly announce the results of any revisions to any of the
forward-looking statements or forward-looking information contained
herein to reflect future results, events or developments.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
Medifocus Contact: John Mon COO Medifocus, Inc. Tel:
410-290-5734 JohnMon@medifocusinc.com
Medifocus (CE) (USOTC:MDFZF)
Historical Stock Chart
From Apr 2024 to May 2024
Medifocus (CE) (USOTC:MDFZF)
Historical Stock Chart
From May 2023 to May 2024